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Endocrine therapy is important for management of patients with estrogen receptor (ER) positive 
breast cancer, however positive ER staining does not reliably predict therapy response. We assessed 
the potential to improve prediction of response to endocrine treatment of a novel test that 
quantifies functional ER pathway activity from mRNA levels of ER pathway-specific target genes. 
ER pathway activity was assessed on datasets from three neoadjuvant treated ER-positive breast 
cancer patient cohorts. Edinburgh: 3 months letrozole, 55 pre-/two-week/post-treatment matched 
samples; TEAM IIa: 3-6 months exemestane, 49 pre-/28 post-treatment paired samples; NEWEST: 16 
weeks fulvestrant, 39 pre-treatment samples. ER target gene mRNA levels were measured in Fresh 
Frozen tissue (Edinburgh, NEWEST) with Affymetrix microarrays, and in Formalin Fixed Paraffin 
Embedded samples (TEAM IIa) with RT-qPCR. 
Approximately one third of ER-positive patients had a functionally inactive ER pathway activity score 
(ERPAS), which was associated with a non-responding status. Quantitative ERPAS decreased 
significantly upon therapy (p<0.001 Edinburgh and TEAM IIa). Responders had a higher pre-
treatment ERPAS and a larger two-week decrease in activity (p=0.02 Edinburgh). Progressive disease 
was associated with low baseline ERPAS (p=0.03 TEAM IIa; p=0.02 NEWEST) which did not decrease 
further during treatment (p=0.003 TEAM IIa). In contrast, the staining-based ER Allred score was not 
significantly associated with therapy response (p=0.2).The ERPAS identified a subgroup of ER-
positive patients with a functionally inactive ER pathway associated with primary endocrine 
resistance. Results confirm the potential of measuring functional ER pathway activity to improve 
prediction of response and resistance to endocrine therapy. 
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Introduction 
Endocrine therapy is one of the mainstays in treatment of both early and metastatic breast cancer. 
Especially, the use of endocrine therapy has resulted in increased survival rates (1–3). Patients are 
currently selected for endocrine therapy using immunohistochemical analysis of estrogen receptor 
(ER) and progesterone receptor (PR) expression (4). Both the American Society for Clinical Oncology 
and the European Society for Medical Oncology advise a threshold of 1% ER-positive tumor cells 
(5,6). In practice, many clinicians and countries choose a threshold of 10% (7). More quantifiable 
analyses like Allred scoring and H-score have been developed and suggested for clinical application, 
but are currently not routinely used (5). 
Despite the success of endocrine therapy in ER-positive breast cancer, up to half of patients do not 
show the expected response (8,9). In addition to cancer tissue heterogeneity, several mechanisms 
have been proposed to explain lack of therapy response, like emergence of ESR1-activating 
mutations or activation of other signal transduction pathways upon pharmacological inhibition of 
the ER pathway (10,11). Standard immunohistochemical analysis detects the presence of nuclear ER 
protein. However, to what extent positive nuclear ER staining indicates actual functional activity of 
the ER pathway has not been addressed satisfactorily. A test to predict response to endocrine 
therapy based on measuring functional activity of the ER pathway is expected to improve decision 
making regarding endocrine therapy and/or alternative therapies (12). 
A number of data-driven RNA-based tests have been developed to assess recurrence risk and predict 
response to endocrine therapy (8,12–14). However, no test is available to measure functional ER 
pathway activity. A knowledge-based Bayesian network computational model for the ER pathway 
has been developed to assess functional activity of this pathway in tumor tissues (15,16). The model 
used mRNA expression levels of 27 high evidence target genes of the ER transcription factor to infer 
the activation state of the ER pathway. Earlier analysis using this ER pathway model showed that 
only part of ER-positive patients had an active pathway, which was associated with lower risk of 
relapse after adjuvant tamoxifen treatment (15). Here we report results on use of this ER pathway 
model to predict and assess response to endocrine therapy in patients with ER-positive breast 
cancer treated in a neo-adjuvant setting. 
Materials and Methods 
Cell line cultures and Estradiol levels in breast cancer tissue 
Estradiol (E2) stimulation experiments, RNA isolation of MCF7, T47D, CAMA1, and BT474 breast 
cancer ER-positive cell lines (ATCC), and measurement of 17-beta-estradiol concentrations in eight 
fresh frozen ER-positive breast tissue samples supplied by Erasmus Medical Center (Rotterdam, The 
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Netherlands) were performed by BioDetection Systems (BDS, Amsterdam). See supplemental 
methods. 
Affymetrix GeneChip microarrays  
Affymetrix HGU133Plus2.0 GeneChip microarray analysis was performed on the samples of the cell 
line experiments as described before (15,17). See supplemental methods. Data were deposited in 
GEO (GSE127760). All Affymetrix (CEL) data (generated in this study or retrieved from GEO) were 
processed using R/BioConductor affy and frma (18–20) packages.  
Edinburgh breast cancer cohort 
Datasets GSE10281 (21) and GSE20181 (14,22) contain data from a cohort of post-menopausal 
patients with large strongly ER-positive (Allred score 5 or more) breast cancers recruited at the 
Edinburgh Breast Unit. Patients underwent neo-adjuvant treatment with 2.5 mg daily letrozole for 
three months. Both sets contain data from fresh frozen biopsies with at least 20% tumor content. 
The Affymetrix HGU133Plus2.0 GSE10281 (AffyP2 Edinburgh) dataset concerns 18 patients with 
samples collected at baseline and after three months of treatment. The Affymetrix HGU133A 
GSE20181 (AffyA Edinburgh) dataset contains gene expression data from biopsies of 62 patients 
collected at baseline and after approximately two weeks and three months of treatment. Clinical 
response was defined as tumor volume reduction of at least 50%, assessed after three months using 
three-dimensional ultrasound (14). Data from six patients was included in both datasets (overlap).  
NEWEST breast cancer cohort.  
Dataset GSE48905 (23) contains data from a multi-center phase II study, in which post-menopausal 
women with operable, locally advanced (T2, 3, 4b; N0-3; M0) ER-positive breast tumors were 
randomized for neo-adjuvant treatment with 500 mg or 250 mg fulvestrant for 16 weeks.  
Tumor core biopsies (fresh frozen tissue) were obtained before start of treatment and Affymetrix 
HGU133Plus2.0 microarrays were performed. Tumor volumes were measured by three-dimensional 
ultrasound and clinical response was classified as complete response (CR, disappearance of all 
lesions), partial response (PR, at least 65% reduction in tumor volume), progressive disease (PD, at 
least 73% increase in tumor volume), or stable disease (SD, none of the previous). 
TEAM IIa breast cancer cohort 
The Dutch TEAM IIa trial is a completed neo-adjuvant phase II prospective trial (24). Briefly, 102 
patients with ER-positive (>50% nuclear ER staining) breast cancer were randomized to receive three 
or six months neo-adjuvant exemestane treatment. Due to slow accrual, the study changed to single 
arm design consisting of 6 months therapy. Standard clinicopathological characteristics, including PR 
and HER2 status, were assessed. Pre-treatment cancer tissue biopsies and post-neo-adjuvant 
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treatment tumor resection specimens were collected and analyzed retrospectively; all tissue 
samples were formalin-fixed paraffin-embedded (FFPE). A total of 49 biopsy and 48 resection 
samples were eligible for analysis, of which 28 samples were paired cases from the same patient 
(Supplemental Figure 5). Primary clinical outcome was reduction in tumor size using RECIST 1.1 
criteria assessed by manual palpation.  
LCM and RNA isolation for FFPE samples from TEAM IIa  
Cancer tissue was separated from surrounding normal and stromal tissue using Laser Capture 
Microdissection (LCM) as described by Espina et al (24). See supplemental methods. In FFPE biopsy 
samples low tumor content limited the amount of available mRNA.  
ER pathway models  
The method used to develop the ER pathway model has been described before (15). The model uses 
mRNA expression levels of ER target genes measured in a tissue sample to infer the odds in favor of 
a transcriptionally active ER transcription factor and, as a consequence, odds in favor of an active ER 
pathway. A Bayesian network representing the ER pathway transcriptional program (15) describes 
(a) how target gene regulation depends on ER transcription complex activity and (b) how expression 
level intensities in turn depend on regulation of the respective target genes. The network consists of 
three types of nodes: (i) ER transcription complex activation node, (ii) target gene regulation node, 
with states ‘down’ and ‘up’, and (iii) expression intensity level nodes, with states ‘low’ and ‘high’, 
each corresponding to an ER target gene. The previously described ER pathway model was 
developed for analysis of Affymetrix HGU133Plus2.0 (AffyP2) data, i.e., target gene expression level 
nodes correspond to AffyP2 probesets (15). During ongoing development towards a diagnostic ER 
pathway test to further improve the sensitivity and specificity of the previously described ER 
pathway model , an additional informative ER target gene (PDZK1) was included (15,25,26). 
Following measurements of breast cancer tissue estrogen levels, the model was adjusted to estradiol 
levels in breast tissue by recalibration on data from MCF7 cultures exposed to 1 nM estradiol (E2) 
from GSE35428 (27, Table 1), instead of 25 nM E2 used to calibrate the original model (28, Table 1). 
Agreement between the original and optimized AffyP2 model was assessed on a collection of 5,395 
breast cancer tissue and cell line samples (Supplemental Table 2). Sensitivity and specificity were 
assessed on 421 breast cancer cell line samples with well-established ER pathway activity 
(Supplemental Table 2). Subsequently, the sensitivity-optimized (1nM) ER pathway model was 
adapted for use on two other mRNA measurement platforms, i.e., Affymetrix HGU133A (AffyA) and 
1-step RT-qPCR (PCR). Adaptation of the ER pathway Bayesian network model between AffyP2 and 
AffyA microarray platforms consisted of selecting probesets that were identical on both platforms 
 
Page 7 of 24 
 
and re-calibrating on samples measured on the respective platforms. For lack of probe availability in 
the AffyA platform, nine probesets and the CDH26 gene were removed from the AffyA 
computational model. The resulting AffyA model retained 50 probesets, representing 27 of the 28 ER 
target genes. The model was calibrated using Affymetrix HGU133A mRNA expression data from 
dataset GSE9936 (29, Table 1). For the qPCR platform, the 28-target gene ER pathway Bayesian 
network was reduced to a smaller network containing the most informative target genes from the 
AffyP2 model (15). The main reason for reducing the number of target genes in the qPCR-based 
model was intended use on FFPE samples. To avoid multiplexing of qPCRs leading to bad qPCR 
performance, multiple separate diagnostic grade qPCRs needed to be developed. Since frequently 
very small samples are available from biopsy FFPE material (as in the TEAMIIA study), the amount of 
RNA isolated from such samples is limiting with respect to the number of qPCRs that can be 
performed. For this reason, a smaller selection of target genes was identified based on evidence of 
the gene being a direct ER target gene, as well as their capacity to differentiate between ER inactive 
and active MCF7 cell cultures. Subsequently this selection was validated by comparing ER pathway 
activity scores obtained with the 28 gene Affymetrix model with a reduced Affymetrix model 
adapted to this limited target gene set. Following this successful initial validation step, RT-qPCR 
(qPCR) assays were developed and validated according to standard procedures for each of the 
selected target genes and a set of reference genes. The Bayesian computational qPCR model (TEAMII 
PCR ER model) was constructed as previously described (15) and calibrated using the BrCa cell line 
calibration set (Table 1). Target gene mRNA expression values from these cell line experiments were 
obtained as described below and used as input to calibrate and validate the TEAMII PCR model. A 
research use prototype qPCR plate, containing reagents for performing the qPCR reactions, was used 
in this TEAM IIa study (Molecular Pathway Dx, Philips, Eindhoven, TEAMII PCR prototype plate). For 
all models, a normalized ER pathway activity score was used, as described under statistical methods.  
In summary: the new 1 nM E2 model for AffyU133P2.0 contains the PDKZ1 gene in addition to the 
gene list described before (15). The 6nM E2 AffyA model lost one gene for which no probesets were 
available on the AffyA platform. For the qPCR-based model, best performing target genes identified 
using AffyU133P2.0 results were selected for further development of the model towards a 
commercially available diagnostic qPCR-based ER pathway test (www.Philips.com/Oncosignal). 
Generation of ER target gene RT-qPCR expression data  
Quantitative expression levels of target genes and reference genes were determined using one-step 
RT-qPCR. See supplemental methods. Normalized quantification cycle (Cq) values were used as input 
for the TEAMII PCR ER pathway model. For the TEAM IIa trial samples, inferred ER pathway activities 
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were calculated in a blinded manner at Philips and returned to Leiden University Medical Center for 
correlation to therapy response. 
DNA sequencing 
Targeted sequencing was used to perform mutation analysis of ESR1 and PIK3CA genes on 28 
available TEAM IIa resection samples with either a paired biopsy sample or a high ER pathway 
activity score on the resection sample. DNA was extracted from whole samples and, if possible, from 
macrodissected samples. See supplemental methods. 
Evaluation of agreement between models 
Agreement between ER pathway models was evaluated by correlating activities obtained by the 
different models on identical sample sets (Table 1). Linear relationship between inferred activity 
scores was assessed by orthogonal regression, assuming equal residual variance. Agreement was 
assessed by Pearson correlation and mean deviations (MD) from the fitted orthogonal regression 
line were used as indication of the measurement error between two models.  
Statistical analysis 
Statistical analysis was performed using R (18) and SPSS 23.0 (IBM). Odds in favor of an active ER 
pathway were transformed into a (base 2) logarithmic scale and then normalized to scores ranging 
from 0 to 100, where 0 corresponds to the lowest and 100 corresponds to the highest odds in favor 
of an active ER pathway that a specific model can infer. This normalization facilitates comparison 
between activity scores obtained on different measurement platforms (Figure 4A/B). Paired t-tests 
were used to assess mean decrease in ER activity between baseline and post-treatment 
measurements, chi-squared tests to assess association between outcome categories and 
dichotomized ER pathway activity, and two sample t-tests and ANOVA to assess ER activity and 
decrease in activity associated with clinical outcome and baseline parameters. All tests assumed 
unequal variance. Unless indicated otherwise, 2-sided p-values and 95% confidence intervals are 
reported. 
Results 
Development and validation of ER pathway models 
Optimization of the previously described ER pathway model included adjusting sensitivity to match 
estradiol (E2) levels present in breast cancer tissue. For this, E2 levels were measured in tissue 
samples of ER-positive breast cancers. Measured concentrations varied between 2.2 and 7 nM E2 
(Supplemental Table 1), in line with concentrations reported by others (30,31). The new AffyP2 ER 
pathway model was calibrated on MCF7 breast cancer cells stimulated with 1 nM estradiol, which 
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lies between E2 concentrations in normal breast (< 1 nM) and in cancer tissue (7 nM in this study). 
Results obtained with this 1 nM-calibrated ER model strongly correlated with results obtained with 
the previously described 25 nM-calibrated ER model (17), corr=0.94, and showed the expected 
increase in sensitivity (from 83% to 91%), without loss in specificity (92%), Supplemental Figures 1 
and 2. The 1 nM model was used for analysis of AffyP2 datasets in this study. Because the ER 
pathway models are measurement platform specific, the AffyP2 model was adapted for use on AffyA 
and qPCR data, as described in the methods section, and compared to the 1 nM AffyP2 reference 
model on sets of technical replicate samples (32, Table 1). Results obtained with the AffyA model 
strongly correlated with results obtained with the 1 nM E2 AffyP2 model on the dataset with 16x2 
technical duplicates (corr=0.80, Supplemental Figure 3A). Differences in sample preparation 
protocols reduced the correlation, illustrating the importance of standardized sample preparation 
procedures (corr=0.63, Supplemental Figure 3B). The TEAMII PCR model correlated well with the 
AffyP2 model on 11 technical duplicates (corr=0.83, Supplemental Figure 4). Mean deviations (MD) 
from the fitted regression lines give an indication of the measurement error between two methods 
and were similar when comparing the AffyP2 1 nM model vs the AffyA and TEAMII PCR models and 
the two AffyP2 models (MD=3.1, 5.6, and 2.3, respectively). 
Functional ER pathway activity before and after neo-adjuvant AI treatment  
Edinburgh cohort 
For the AffyP2 Edinburgh cohort, ER activity score decreased significantly upon letrozole treatment 
(41.6 vs 28.4), mean decrease of 13.2 (CI=9.7-16.8, paired t-test p-value < 0.001, Figure 2A). ER 
activity scores at start of treatment were positively correlated to decrease in ER activity after three 
months of therapy, indicating that the higher the baseline ER activity, the higher the decrease in ER 
activity upon treatment (corr=0.88, Figure 2B). Clinical response data were not available for this 
cohort. 
Similarly, in the AffyA dataset of the Edinburgh cohort (Table 2, Figure 3A/B), ER pathway activity 
score decreased significantly between baseline and two weeks (46.9 vs 39, mean decrease of 7.9, 
paired t-test p-value <0.001) and between baseline and three months of letrozole (46.9 vs 39.5, 
mean decrease of 7.5, paired t-test p-value <0.001). No significant difference in activity was seen 
between two weeks and three months of treatment, indicating an early and maintained response to 
letrozole for the patient group as a whole. Again, baseline and decrease in ER activity were positively 
correlated, both after two weeks and three months of treatment (corr=0.74 and 0.83, respectively, 
Figure 3C-D). In this cohort, clinical response data were available and both baseline ER pathway 
activity and decrease in ER activity after two weeks of AI treatment were significantly higher in 
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clinical responders to letrozole than in non-responders (p=0.02, Table 2, Figure 3B/E). Upon letrozole 
treatment, average ER activity scores decreased in responders to the same low ER activity level of 
non-responders and remained at such level up to the three months measurement point (Figure 
3A/B/F).  
Using a threshold for ER activity, as described before (15), enables analysis at individual patient level 
with respect to clinical response to letrozole. To evaluate the predictive value of the ER pathway 
score in an unbiased way, a threshold of 42.7 was set prior to analysis. This value corresponds to an 
odds of 1:1, the point where the inferred probability of the ER pathway being active is 50%. This 
preset value is very close to 41.5, the best cutoff point obtained by ROC analysis of the present 
dataset. Using the predefined 42.7 threshold, 69% of patients (n=38) had an active pre-treatment ER 
pathway. This proportion decreased to 24% (n=13) after two weeks and slightly increased to 31% 
(n=17) after three months of treatment (Table 2). At baseline, 77% (n=34) of clinical responders had 
an active ER pathway, against only 36% (n=4) of non-responders (Table 2). Accordingly, a baseline ER 
active state was significantly associated with response to therapy (chi-square p-value=0.009, Table 
2). Univariate logistic regression analysis reported an odds ratio (OR) of 5.9 (CI=1.4-24.5, p-
value=0.01) on the dichotomous active/inactive ER status and a protective OR of 0.35 (CI=0.13-0.95, 
p-value 0.02) for an increase in 10 points in the ER pathway activity score. As reference, relation of 
response to established markers (baseline tumor grade and ER Allred score) was also analyzed 
(Supplemental Table 3). While tumor grade was associated with response to therapy (chi-square test 
p-value=0.03), ER Allred score was not (chi-square p-value=0.2). Sample size was small for reliable 
multivariate analysis, but initial analysis indicated that the ER pathway score remained significant 
after adjustment for grade and Allred score (Supplemental Table 4).  
Analysis of this cohort not only illustrated the expected decrease in ER activity upon effective 
letrozole treatment, but also that roughly one third of ER-positive patients had a functionally 
inactive ER pathway, associated with non-responder status. Finally, in the first two weeks of 
letrozole treatment, ER pathway activity decreased in the majority of patients (85%, n=47), while 
between two weeks and three months ER activity slightly increased in the majority of patients (60%, 
n=33, Table 2). In line, the observed decrease in ER activity from baseline to two weeks was higher in 
responders than non-responders (9.3 vs 2.7, p-value=0.02), and remained higher in responders after 
three months of treatment (8.6 vs 2.9, p-value=0.13).  
TEAM IIa cohort 
For the TEAM IIa cohort (Table 3) the average ER pathway activity score was 42.2 at baseline (n=49) 
and decreased to 33.9 (n=48) after exemestane therapy. In the 28 paired samples (before and after 
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therapy), mean decrease in activity score was 9.1 (paired t-test p-value < 0.001). In this cohort, again 
a positive but weak correlation was found between baseline ER activity and decrease in ER activity 
during treatment (corr=0.29, Supplemental Figure 6).  
To test the value of the TEAMII PCR ER pathway model to predict response to aromatase inhibitors 
(AI), ER pathway activity was correlated to decrease in tumor size assessed by manual palpation 
(Figure 4D, Supplemental Table 6). Patients with progressive disease (PD) during AI treatment had a 
significantly lower ER pathway activity at baseline (28.4, n=3) compared to patients with non-PD 
(44.6, n=35); t-test p-value=0.03 (Supplementary Table 4, response assessed at last measurement). A 
relation between pre-treatment ER pathway activity scores and clinical response was already 
present at three months exemestane (non-PD=44.6, n=27 vs PD=28.7, n=3; p-value=0.04, 
Supplemental Table 6, response assessed at 3 months).  
Palpation-based response assessment was available for 23 patients with paired biopsy/resection ER 
pathway scores (Figure 4A/C). During AI treatment, ER pathway activity decreased in all six patients 
with complete remission (CR). In two of seven patients with partial response (PR) and in three of 
eight patients with stable disease (SD), an increase in ER activity was measured after neo-adjuvant 
therapy, indicating failure of blocking ER pathway activity at least at the time of surgical resection. 
For the two patients with PD with available paired samples, ER activity was low before and had not 
changed after treatment. Decrease in activity score was higher in non-PD (9.9, n=21) than PD (−0.16, 
n=2), paired t-test p-value=0.003 (Figure 4C). Though ER pathway activity did not differ significantly 
at baseline for CR, PR, and SD patients, a clear distinction was observed between CR/PR and PD 
patients (Figure 4A). In addition, decrease in ER activity was larger in CR patients, becoming 
gradually smaller in PR and SD patients (Figure 4D).  
For this cohort, available clinical data and sample size was too limited for extensive analysis. 
However, brief examination of the association of response to established risk markers did not 
indicate any of the available markers were associated to PD, and ER activity score remained 
associated to PD after adjustment.    
NEWEST cohort 
For the NEWEST cohort, Affymetrix data were only available from biopsies prior to start of neo-
adjuvant fulvestrant. Data were analyzed using the AffyP2 ER model (Figure 4B). Baseline ER activity 
score was 28.7 in the 2 PD samples vs 36.6 in the 37 non-PD patients (difference of 8.0 CI=2.2-13.7, 
t-test p-value=0.02), similar to results of the TEAM IIa study. Again, there was no significant 
difference between PR and SD patients. 
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Relation between ER pathway activity and PR IHC staining  
Combined ER/PR positive IHC staining is generally thought to be a better indicator of response to 
endocrine treatment than ER status alone. Therefore, combined positive staining might be a more 
accurate predictor of an active ER pathway. Indeed, the PR positive biopsy samples of the TEAM IIa 
cohort (n=36, 73%), had significantly higher ER activity than the ER+/PR- samples (48.7 vs. 34.3, two 
sample t-test p-value=0.003) and the decrease in ER activity after treatment was larger in the 
ER+/PR+ group, although this did not reach significance (Supplemental Table 3). However, baseline 
PR protein staining alone did not correlate with response to AI therapy, neither in the TEAM IIa 
cohort (this study) nor in the Edinburgh cohort (reported in 33).  
Mutation analysis of ESR1 and PIK3CA genes in TEAM IIa cohort 
ESR1 and PIK3CA mutations could be assessed in 15 samples (13 patients) of the TEAM IIa study 
(Supplemental Figures 7 and 8); remaining samples were of insufficient quality. Though non-
synonymous ERS1 SNVs were only found in patients with partial response or stable disease, no 
literature evidence as to their functionality was found. A known PIK3CA (H1047R) activating 
mutation was detected in one CR and one SD patient. 
Discussion 
We previously described the development of a new method to quantitatively measure activity of the 
ER pathway in a tissue sample using a computational model that interprets measured ER target gene 
mRNA levels (15). In the current study, its use to predict response to neo-adjuvant endocrine 
treatment in ER-positive breast cancer patients was evaluated, analyzing two clinical studies from 
Edinburgh (14,21), the Dutch TEAM IIa cohort (24) and the NEWEST study (23). For this purpose, the 
ER pathway model was adjusted to match sensitivity to E2 concentrations in cancer tissue, and 
adapted to the different mRNA measurement platforms used in these clinical studies. After freezing 
the models, analysis of the independent patient cohorts was performed to provide per sample a 
quantitative ER pathway activity score.  
AI treatment reduced ER pathway activity 
In all three clinical studies for which pre- and post-treatment data were available, AI treatment 
induced a decrease in ER pathway activity scores, and the decrease was already maximal after two 
weeks of treatment. In the studies for which clinical response data were available, the ER activity 
score prior to treatment correlated with clinical response. In the AffyA Edinburgh cohort, a high ER 
activity score was associated with favorable clinical response to AI. In the TEAM IIa and NEWEST 
studies, low ER pathway activity score was associated with progressive disease under AI and 
fulvestrant treatment, respectively. In general, patients with higher activity scores responded better 
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to endocrine treatment than patients with lower activity scores, and treatment-induced decrease in 
ER pathway activity was largest in clinical responders and smallest in progressive disease patients. 
These observations are in accordance with broad evidence that AI and fulvestrant therapies are 
effective in patients with an active ER pathway driving tumor growth, by interfering with production 
of estradiol, and by blocking of ER transcriptional activity and degrading ER, respectively (9,34). An 
inactive or minimally active ER pathway is expected to be associated with primary resistance and 
progressive disease under endocrine therapy, as we observed. Results are also in line with our 
earlier finding that ER-positive breast cancer patients with low ER pathway scores, treated with 
adjuvant tamoxifen, have a shorter relapse free survival (15).  
In the TEAM IIa study, ER activity scores were not significantly different between CR, PR, and SD 
groups. A contributing factor may have been inaccuracy in assessment of tumor size by manual 
palpation, which was performed by different MDs at non-fixed time points during treatment. 
Nevertheless, a detailed comparison of tumor size at resection versus estimated size by palpation, 
mammography, US, and MRI in the TEAM IIa cohort suggested palpation as most accurate 
measurement method (35). Additionally, in the NEWEST study, three-dimensional ultrasound 
assessment of tumor volume was used to assess clinical response, and again low ER pathway activity 
was associated with progressive disease, while ER pathway activity score could not statistically 
separate PR and SD. However, in both clinical studies, best responder patients (respectively CR and 
PR) were clearly distinguishable from PD patients by higher ER pathway activity. 
Positive ER/PR IHC staining is generally thought to be a more reliable indicator of response to 
endocrine therapy than positive ER staining alone. However, while PR staining did correlate with ER 
pathway activity, it did not correlate with response to AI, indicating that combined ER/PR IHC alone 
is insufficient to decide on an active ER pathway and endocrine treatment, in agreement with clinical 
experience (36). This is likely due to the indirect relationship between ER transcriptional activity and 
expression level of the actual PR protein (37).  
The Allred score for ER immunohistochemistry staining has also been described as a predictive 
marker for neoadjuvant hormonal therapy response, with improved response at Allred scores higher 
than 5 (3). In the AffyA Edinburgh cohort for which this score was available, no relation with 
response to therapy was found, probably due to intentional pre-selection bias towards high Allred 
scores to enrich the responders group (33).  
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 Persistent ER pathway activity under AI treatment  
In a subgroup of patients from the AffyA Edinburgh and TEAM IIa cohorts (16% and 25%, 
respectively), ER pathway activity had increased at the end of AI treatment, indicating failure of 
blocking ER pathway activity, at least at the time of surgical resection or last biopsy. Possible 
explanations for measuring persistent ER pathway activity under AI are lack of compliance, stopping 
therapy prior to surgical resection, tumor heterogeneity, and emerging endocrine resistance. In both 
studies, patients were followed closely and compliance was estimated as high by the treating 
oncologists, however non-compliance cannot be excluded with certainty. Tumor heterogeneity with 
respect to ER active and ER inactive cancer cell clones is another explanation, as shown recently in a 
preliminary study (38). A side study comparing ER pathway activity in different areas of resected 
tumor from six TEAM IIa patients showed a variation in the ER pathway score of 9 points or more in 
four patients (Supplemental Figure 9). Resistance mechanisms such as ER activating mutations and 
activation of other tumor driving signaling pathways are well-known consequences of endocrine 
therapy, and the incidence of ER-activating mutations lies around 12% after treatment with 
aromatase inhibitors (39,40). The observed increase in ER pathway activity score between two 
weeks and three months treatment in the AffyA Edinburgh study, especially in patients with an initial 
reduction in ER score, is suggestive of ER-activating ESR1 mutations, unfortunately, no mutation 
information was available. In the TEAM IIa study, due to lack of sufficient tissue, ESR1 mutations 
could only be assessed in a few samples by targeted sequencing and only ESR1 SNVs with unknown 
functionality and unrelated to AI resistance or clinical response were identified. Sequencing of 
PIK3CA mutations revealed two known PIK3CA activating mutations, also without relation to 
response. These results emphasize the challenge of interpreting mutations with respect to functional 
impact, in line with recent clinical findings (41).  
ER pathway model performance using different mRNA measurement techniques 
An important reason for successful adaptation of the ER pathway model to other mRNA 
measurement platforms than the original AffymetrixU133Plus2.0, is the Bayesian network model 
approach based on causal relationships between the ER transcription factor and well-established ER 
target genes (15,16). The differences between this knowledge-based approach to develop signaling 
pathway tests, and data-driven methods, have been described and discussed before (15,17,42,43). 
In brief, data-driven efforts to generate pathway gene expression signatures, such as Gene Set 
Enrichment Analysis (GSEA) and DAVID, have been typically based on discovery of non-causal 
associations between expressed genes and a pathway, by analyzing datasets with more or less 
specified relationships to the pathway (44–46). Such methods are prone to finding spurious 
associations and carry a high risk of overfitting, which interferes with biological validation and 
 
Page 15 of 24 
 
performance on independent datasets, and with adaptation to other gene measurement platforms 
(47). In contrast, the Bayesian ER pathway model was biologically validated can calculate the ER 
pathway activity score of an individual sample despite variations in the expressed target gene 
subset, and performance is relatively independent of the used mRNA measurement platform. The 
latter is illustrated by the highly comparable results obtained by analysis of the different patient 
cohorts, where ER pathway activity was measured using different mRNA measurement platforms. 
For example in the TEAM IIa and NEWEST cohorts, low ER activity scores predicted progressive 
disease under endocrine therapy, irrespective of being measured on fresh frozen samples with 
Affymetrix microarrays, or on FFPE samples with qPCR.  
Predicting response to endocrine therapy 
Despite strongly positive ER staining, some patients fail to respond to neoadjuvant endocrine 
therapy, potentially resulting in progressive disease. By measuring ER pathway activity, we were able 
to identify such patients based on their low ER pathway activity score. By providing additional 
evidence that ER positive breast cancers do not always have high ER pathway activity, we provide a 
rational explanation for the clinical issue of non-responders. Analysis of three independent clinical 
breast cancer cohorts confirmed the potential value of measuring functional ER pathway activity to 
predict response to endocrine therapy. The Bayesian computational models for ER pathway activity, 
adapted to different measurement platforms, revealed comparable clinical results on fresh frozen 
tissue as well as FFPE samples. The ER pathway activity score has clinical value as a continuous 
measure: the higher the score, the more likely that the ER pathway was active in the analyzed 
sample and the more likely that the patient responded to anti-hormonal treatment. In a clinical 
sample consisting of a mixture of cells, an absolute ER pathway activity threshold is arbitrary, since 
the activity score represents averaged ER pathway activity in the cell mixture, thus depending on 
percentage of cancer cells and their level of ER pathway activity. In the future, a clinically useful 
approach might be the use of tertiles of activity scores, allowing middle tertile scores to indicate 
uncertain treatment response. 
The frequently extremely small FFPE samples from pretreatment biopsies reflect the routine 
diagnostic situation and are a point of concern. Current developments are directed towards 
improvement of signaling pathway analysis on such samples. Further clinical validation of the ER 
pathway test is ongoing, as well as elucidating the role of other signaling pathways, such as the PI3K 
pathway, in hormonal resistance (17,42).  
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Tables 
Table 1: Datasets used in this study.  
AffyA: Affymetrix HGU133A; AffyP2: Affymetrix HGU133Plus2.0.  
Set Platform Use Set description References  
GSE8597 AffyP2  Calibration of 
original  
25 nM E2 AffyP2 
model 
MCF7 cell line treated with 25 nM 
E2 (N=4) or DMSO (N=4) for 24h. 
(28) 
GSE35428 AffyP2  Calibration of 
optimized 
1 nM E2 AffyP2 
model 
MCF7 cell line treated with 1 nM E2 
(N=10) or ethanol (N=10) for 24h. 
(27) 
GSE9936 AffyA Calibration of  
AffyA 6 nM E2 
model 
MCF7 cell cultures treated with 6 
nM E2 (N=3) or vehicle (N=3) for 
24h. 
(29) 
BrCa cell line 
calibration  
RT-qPCR Calibration of  
qPCR TEAM IIa 
model 
MCF7 cell cultures treated with 1 
nM E2 (N=4) or vehicle (N=4) for 
16h. 
This study 
BrCa cell line 
test 




and TEAMII PCR 
models 
MCF7, T47D, CAMA1 and BT474 cell 
lines treated with 1 nM E2, 10 nM 








and AffyA models 
Biological replicate samples from 16 
breast cancer patients processed by 
both platforms in two different 






AffyP2 Correlation with ER 
activity decrease 
during AI and 
agreement with 
AffyA model 
Biopsy samples of 18 patients of the 
Edinburgh cohort, collected at 
baseline and after 3 months 
neoadjuvant treatment with 
letrozole (N=18x2 correlation with 






AffyA Correlation with AI 
response data and 
agreement with 
AffyP2 model 
Biopsy samples of 55 patients of the 
Edinburgh cohort, collected at 
baseline and after 3 months 
neoadjuvant treatment with 
letrozole (N=55x3 correlation with 
AI; N=6x2 agreement with AffyP2 
model). 
(14,22) 




Correlation with AI 
therapy response 
49 biopsy and 48 resection samples 





AffyP2 Correlation with 
fulvestrant 
response 
42 samples from patients treated 
for 16 weeks with either 500 mg or 
250 mg of the selective estrogen 






Table 2: Changes in ER pathway activity scores upon AI treatment. 
ER pathway activity score and decrease in activity score for the 55 complete cases of AffyA Edinburgh 
dataset (GSE20181, 44 responders and 11 non-responders). R: responders, NR: non-responders; av: 
average, sd: standard deviation. Base-2w: change in ER pathway activity between initiation and two 
weeks of treatment; Base-3m: change in ER pathway activity between initiation and three months of 
treatment; 2w-3 m: change in ER pathway activity between two weeks and three months of 
treatment. T-tests reported as difference (CI), p-value. 
ER activity status  
 
  score     paired t−test (baseline 
vs time point) All active (%) inactive (%)   av sd Range  
Baseline 38 (69%) 17 (31%)   46.9 8.9 [32.1, 69.9]    
Two weeks 13 (24%) 42 (75%)   39.0 6.2 [26.9, 53.8] 7.9 (5.7, 10.2), <0.001 
  Three months 17 (31%) 38 (69%)   39.5 5.3 [27.6, 49.4] 7.5 (5.0, 9.9), <0.001 
Stratified by response      t−test (R vs NR) 
Baseline          
R (n=44) 34 (77%) 10 (23%)   48.2 8.9 [32.1, 69.9] 
6.5 (1.2, 11.7), 0.02 
  NR (n=11) 4 (36%) 7 (64%)   41.8 7.0 [33.6, 53.2] 
Two weeks          
R 11 (25%) 33 (75%)   39.0 6.2 [26.9, 53.8] 
−0.1 (−3.9, 3.7), 0.95 
  NR 2 (18%) 9 (82%)   39.1 5.1 [28.1, 46.3]] 
Three months          
R 14 (32%) 30 (68%)   39.6 4.8 [27.6, 48.3] 
0.8 (−4.0, 5.7), 0.72 
  NR 3 (27%) 8 (72%)   38.8 7.0 [28.3, 49.4] 





  decrease in score 
 
decrease increase   av sd Range 
  
  Base − 2 w 47 (85%) 8 (15%)   7.9 8.3 [−9.1, 25.0]    
Base − 3 m 46 (84%) 9 (16%)   7.5 8.9 [−15.0, 28.0] 
 
  2 w − 3 m 22 (40%) 33 (60%)   −0.47 4.9 [−12.0, 8.7]   
Stratified by response   av Sd Range t−test (R vs NR) 
Base − 2 w          
R 39 (89%) 5 (11%)   9.3 8.0 [−7.0, 25.0] 
6.6 (1.3, 11.8), 0.02 
  NR 8 (73%) 3 (27%)   2.7 7.2 [−9.1, 13.0] 
Base − 3 m         
  R 38 (86%) 6 (14%)   8.6 8.1 [−9.7, 28.0] 
5.6 (−1.8, 13), 0.13 
  NR 6 (55%) 5 (45%)   2.9 11.0 [−15.0, 21.0] 
2 w − 3 m             
R 17 (39%) 27 (61%)   −0.65 4.8 [−12.0, 8.7] 
-0.91 [-4.9, 3.0], 0.6 







Table 3: ER pathway score at baseline and tumor resection for the TEAM IIa cohort.  
Measurements are from the TEAMII PCR platform. CR: complete remission, PR: partial remission, SD: stable disease, PD: progressive disease; av: average, sd: 
standard deviation. N: number of samples available for pathway analysis. Decrease in ER pathway activity score was calculated for paired samples from the 
same patient. Sample availability indicated as baseline only: number of patients with only a biopsy sample; paired: number of patients with paired biopsy 
and resection sample; resection only: number of patients with only resection sample.  





only N av sd range N av sd Range N av sd range 
All 21 28 20 49 42.2 11.6 [9.9, 62.2] 28 9.1 12.8 [−11.2, 31.5] 48 33.9 14.0 [5.6, 59.8] 
 Stratified by response assessed by palpation at last measurement 
All 15 23 17 38 43.3 10.9 [18.9, 62.2] 23 9.0 13.3 [−11.2, 31.5] 40 32.6 13.5 [5.6, 59.8] 
CR 5 6 3 11  47.6 7.8 [38.9, 62.2] 6 20.0 9.0 [7.1, 27.7] 9 28.7 10.1 [13.4, 46.1] 
PR 5 7 8 12 41.8 13.0 [18.9, 56.3] 7 6.4 11.7 [−9.2, 25.4] 15 31.8 16.5 [5.6, 59.8] 
SD 4 8 5 12 44.5 9.1 [25.8, 56.0] 8 5.4 15.2 [−11.2, 31.5] 13 38.9 10.2 [20.3, 54.4] 






Figure 1: Schematic representation of ER pathway model network.  
Left: Schematic of Affymetrix HGU133A (AffyA) model network, only genes and probesets present in the AffyA 
platform were kept. Center: Node type description. Right: Schematic of TEAMII PCR model, RT-qPCR assays were 
developed for a subset of target genes of the AffyP2 model.  
 
Figure 2: ER pathway activity scores significantly decreased following aromatase inhibitor treatment.  
Scores on AffyP2 Edinburgh dataset (GSE10281, n=18) were calculated using the 1nM E2 AffyP2 model. (A) individual 
patients’ line plots of ER activity at baseline and at three months (mean decrease = 13.2, CI=9.7-16.8), *** indicates 
paired t-test p-value < 0.001). (B) ER activity at baseline versus decrease in activity after three months of therapy 
(corr=0.88, CI=0.71-0.96, p<0.001).  
 
Figure 3: ER pathway activity scores are significantly lower at baseline and two weeks in non-responding than 
responding tumors in the AffyA Edinburgh (GSE20181) dataset.  
ER pathway activity was measured with the AffyA model. (A) Individual patients’ line plot of ER pathway activity at 
baseline and after two weeks and three months of treatment. Solid lines: activity went down during treatment; 
dashed lines: activity went up during treatment. (B) ER activity score as a function of treatment time for responders 
(left panel, blue) and non-responders (right panel, red). C/D: Relationship between ER activity at baseline and 
decrease in ER activity (C) at two weeks (corr=0.74, CI=0.6-0.84, p-value<0.001) and (D) at three months (corr=0.83, 
CI=0.72-0.89, p-value<0.001) of letrozole treatment (n=55). (E) Box plots of ER pathway activity in responders and 
non-responders at baseline. (F) Decrease in ER pathway activity score, between baseline and two weeks (left) and 
between baseline and three months (right) of treatment. Resp/blue: responders; Non-Resp/red: non-responders.  
***: t-test p-value < 0.001; *: t-test p-value < 0.05. 
Figure 4: In patients with progressive disease ER pathway activity scores are significantly lower and do not change 
after treatment.  
(A) ER activity score at baseline in patients of the TEAM-IIA cohort measured with the TEAMII qPCR model, (B) ER 
activity score at baseline in patients of the NEWEST cohort measured with the AffyP2 model, (C) Team IIA cohort, 
individual ER pathway activity score as function of treatment time. (D) Team IIA cohort, decrease in pathway activity 
score from baseline to tumor resection, stratified by response assessed by palpation at last measurement. CR, blue: 




activity went down during treatment; dashed lines: activity went up during treatment. **: t-test p-value < 0.01; *: t-
test p-value < 0.05. 
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N 11 12 12 3 
av 47.6 41.8 44.5 28.4 
sd 7.8 13 9.1 6.5 
N 15 22 2 
av 36.4 36.8 28.7 
sd 8.0 10.1 2.0 
N 6 7 8 2 
av 20 6.4 5.4 0.16 
sd 9 11.7 15.2 2.0 
